News & Updates
Filter by Specialty:
Oral ritlecitinib shows promise against nonsegmental vitiligo
The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.
Oral ritlecitinib shows promise against nonsegmental vitiligo
17 Nov 2022
Cinnamic aldehyde, alcohol cause reactions in fragrance allergy
A prospective study has revealed that cinnamic aldehyde and cinnamic alcohol are the most common allergens that cause immediate and delayed reactions among patients with allergic contact dermatitis to fragrance. In addition, reactions to benzyl alcohol, sorbic acid, and coumarin are usually seen in immediate patch tests.
Cinnamic aldehyde, alcohol cause reactions in fragrance allergy
12 Nov 2022
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
Long-term tapinarof use proven safe, effective in plaque psoriasis
Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.
